Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Collaborating with Frazier Healthcare Partners, the team spun out a new company dubbed HilleVax to take Takeda’s norovirus vaccine into Phase 3 trials.
With the Alzheimer’s Association International Conference conference last week, there were plenty of clinical trial news and updates. Here’s a look.
As Gilead gets ready to open its doors to its new operations site in North Carolina, the company reported its product sales for the second quarter increased 21% year-over-year primarily driven by Veklury.
The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
The United States and other wealthy nations now stand at an important place in their COVID-19 vaccine campaigns. The question largely turns to vaccinating the remainder of the population – namely, those under 12 years.
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.
bluebird bio and National Resilience signed a strategic alliance around cell therapies. As part of the deal, Resilience is buying bluebird’s manufacturing facility in Research Triangle Park, keeping more than 100 staffers.
Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today.
Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.